Assess an author's claims

Author review: Yuanhui Li — quick verdict

Based on the provided OpenAlex snapshot, at least one researcher named "Yuanhui Li" (OpenAlex A5061241836) has a substantial publication record (146 works, 4,371 citations, h-index 34); the corpus you supplied also includes a high-quality translational oncology paper (Double‑Hit Lymphoma combination therapy) useful to assess experimental rigor and reporting standards DHL combination therapy paper

Author Review — Yuanhui Li

This review synthesizes the supplied OpenAlex author snapshots and the detailed translational oncology paper (DHL: XPO1+BCL2) to evaluate scientific strength, rigor, and communication. Visual-first layout below: metrics, publication mix, a methodological critique grounded in the DHL paper, and actionable improvement suggestions.

What the metrics show (visual)

• At least one author record named "Yuanhui Li" (OpenAlex A5061241836) has a mid-high publication volume (146 works) and moderate-to-high citation impact (4,371 citations; h-index 34) — consistent with an established researcher in their field.
• Multiple OpenAlex matches with the same name illustrate the common author-name ambiguity risk; care is required when attributing specific papers or metrics to a single person.

Focused, evidence-based critique using the DHL translational paper

We use the detailed DHL preclinical study as a concrete example to judge experimental standards and reporting; the following points summarize strengths, weaknesses, and reproducibility considerations drawn directly from the paper's methods and results DHL combination therapy paper

Implications for assessing an author named "Yuanhui Li"

1. Name disambiguation is crucial: multiple OpenAlex matches with the same name indicate risk of conflating different researchers; always validate ORCID or institutional affiliation before attributing papers or metrics.
2. Publication & citation counts (e.g., 146 works / 4,371 citations / h-index 34 for one record) suggest an experienced researcher, but metrics alone do not prove experimental rigor — inspect representative primary papers (example: DHL paper) for methods transparency and reproducibility signals.
3. When evaluating scientific strength, weight primary-data quality (sample sizes, controls, disclosure of reagents, statistical transparency) higher than venue or raw citation totals.

Concrete, ranked recommendations to improve scientific strength & reproducibility

1. Provide full methods and reagents in supplementary materials (primer sequences, antibody catalog numbers, raw images, full blots) to support reproducibility.
2. Use multiple independent PDX models and, where feasible, syngeneic or humanized immune‑competent models to test translational robustness of preclinical findings.
3. Apply pre-registered protocols and independent replication (blinded scoring of IHC/BLI) to reduce bias and strengthen claims.
4. For bibliometric attribution, always include ORCID in publications and OpenAlex/ORCID crosswalks to avoid name ambiguity.